References
- 1. Gopal S, Joseph R, Santhosh VC, Kumar VV, Joseph S, Shete AR. Prevalence of gingival overgrowth induced by antihypertensive drugs: A hospital-based study. J Indian Soc Periodontol. 2015;19(3):308-11.
- 2. Trackman PC, Kantarci A. Molecular and clinical aspects of drug-induced gingival overgrowth. J Dent Res. 2015; 94 (4): 540-546.
- 3. Goriuc A, Foia LG, Minea B, Luchian AI, Surdu AE, Toma V, Costuleanu M, Mârţu I. Drug-induced gingival hyperplasia - experimental model. Rom J Morphol Embryol. 2017; 58 (4): 1371-1376.
- 4. Dongari-Bagtzoglou A; Research, Science and Therapy Committee, American Academy of Periodontology. Drug-associated gingival enlargement. J Periodontol. 2004;75(10):1424-31.
- 5. Tonsekar P, Tonsekar V. Calcium-Channel-Blocker- Influenced Gingival Enlargement: A Conundrum Demystified. Oral. 2021;1(3):236-49.
- 6. Seymour RA, Jacobs DJ. Cyclosporin and the gingival tissues. J Clin Perio. 1992; 19: 1–11.
- 7. Tamargo J, Ruilope LM. Investigational calcium channel blockers for the treatment of hypertension. Expert Opin Investig Drugs. 2016;25(11):1295-1309.
- 8. McKeever RG, Hamilton RJ. Calcium Channel Blockers. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
- 9. Lin Y, Ma L. Blood pressure lowering effect of calcium channel blockers on perioperative hypertension: A systematic review and meta-analysis. Medicine (Baltimore). 2018;97(48):e13152.
- 10. Wang AL, Iadecola C, Wang G. New generations of dihydropyridines for treatment of hypertension. J Geriatr Cardiol. 2017;14(1):67-72.
- 11. Volpe M. Calcium Channel Blockers for the Clinical Management of Hypertension. High Blood Press Cardiovasc Prev. 2018;25(1):1-3.
- 12. Wing LMH. Calcium channel antagonists. Aust Prescr 1997;20:5-8.
- 13. Russell RP. Side effects of calcium channel blockers. Hypertension. 1988;11(3 Pt 2):II42-4.
- 14. Dustan HP. Calcium channel blockers. Potential medical benefits and side effects. Hypertension. 1989;13(5 Suppl):I137-40
- 15. Bharti V, Bansal C. Drug-induced gingival overgrowth: The nemesis of gingiva unravelled. J Indian Soc Periodontol. 2013; 17 (2): 182-187.
- 16. Tungare S, Paranjpe AG. Drug Induced Gingival Overgrowt. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2021.
- 17. Tahamtan S, Shirban F, Bagherniya M, Johnston TP, Sahebkar A. The effects of statins on dental and oral health: A review of preclinical and clinical studies. J Transl Med. 2020; 18: 1–42.
- 18. Quach H, Ray-Chaudhuri A. Calcium channel blocker induced gingival enlargement following implant placement in a fibula free flap reconstruction of the mandible: A case report. Int J Implant Dent. 2020; 6: 1–5.
- 19. Asif SM, Shaik N, Barthunia B, Kaleem SM, Zakirulla M, Kota MZ, Baig FAH. Nifedipine induced gingival enlargement in an edentulous patient: a case report with one year follow up. BMC Oral Health. 2018;18(1):227.
- 20. Casetta I, Granieri E, Desiderá M, Monetti VC, Tola MR, Paolino E, Govoni V, Calura G. Phenytoin-induced gingival overgrowth: a community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology. 1997;16(6):296-303.
- 21. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: a community-based study. J Periodontol. 1999;70(1):63-7.
- 22. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol. 1992;19(5):311-4.
- 23. Fattore L, Stablein M, Bredfeldt G, Semla T, Moran M, Doherty-Greenberg JM. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dentist. 1991;11(3):107-9.
- 24. Nery EB, Edson RG, Lee KK, Pruthi VK, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol. 1995;66(7):572-8.
- 25. Bajkovec L, Mrzljak A, Likic R, Alajbeg I. Drug-induced gingival overgrowth in cardiovascular patients. World J Cardiol. 2021;13(4):68-75.
- 26. Ishida H, Kondoh T, Kataoka M, Nishikawa S, Nakagawa T, Morisaki I, Kido J, Oka T, Nagata T. Factors influencing nifedipine-induced gingival overgrowth in rats. J Periodontol. 1995;66(5):345-50.
- 27. Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol. 2000;27(4):217-23.
- 28. Pasupuleti MK, Musalaiah SV, Nagasree M, Kumar PA. Combination of inflammatory and amlodipine induced gingival overgrowth in a patient with cardiovascular disease. Avicenna J Med. 2013;3(3):68-72.
- 29. Seymour RA, Heasman PA. Drugs and the periodontium. J Clin Periodontol. 1988;15(1):1-16.
- 30. Seymour RA, Jacobs DJ. Cyclosporin and the gingival tissues. J Clin Periodontol. 1992;19(1):1-11.
- 31. Aldemir NM, Begenik H, Emre H, Erdur FM, Soyoral Y. Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. Afr Health Sci. 2012;12(4):576-8.
- 32. Tejnani A, Gandevivala A, Bhanushali D, Gourkhede S. Combined treatment for a combined enlargement. J Indian Soc Periodontol. 2014;18(4):516-9.
- 33. Gaur S, Agnihotri R. Is dental plaque the only etiological factor in Amlodipine induced gingival overgrowth? A systematic review of evidence. J Clin Exp Dent. 2018;10(6):e610-e619
- 34. Takeuchi RE, Matsumoto HI, Akimoto YO, Fujii AK. The inhibitory action of amlodipine for TNF-α-induced apoptosis in cultured human gingival fibroblasts. Oral Ther. Pharmacol. 2012;31:45-52.
- 35. Livada R, Shiloah J. Calcium channel blocker-induced gingival enlargement. J Hum Hypertens. 2014;28(1):10-4.
- 36. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4(1):1-6.
- 37. Daley TD, Wysocki GP. Cyclosporine therapy. Its significance to the periodontist. J Periodontol. 1984;55(12):708-12.
- 38. Ellis JS, Monkman SC, Seymour RA, Idle JR. Determination of nifedipine in gingival crevicular fluid: a capillary gas chromatographic method for nifedipine in microlitre volumes of biological fluid. J Chromatogr. 1993;621(1):95-101
- 39. Bharti V, Bansal C. Drug-induced gingival overgrowth: The nemesis of gingiva unravelled. J Indian Soc Periodontol. 2013;17(2):182-7.
- 40. Meisel P, Giebel J, Kunert-Keil C, Dazert P, Kroemer HK, Kocher T. MDR1 gene polymorphisms and risk of gingival hyperplasia induced by calcium antagonists. Clin Pharmacol Ther. 2006;79(1):62-71.
- 41. Uzel MI, Kantarci A, Hong HH, Uygur C, Sheff MC, Firatli E, Trackman PC. Connective tissue growth factor in drug-induced gingival overgrowth. J Periodontol. 2001;72(7):921–931.
- 42. Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia. A histochemical and ultrastructural study. J Periodontol 1985; 56(4):211–215.
- 43. Ramírez-Rámiz A, Brunet-LLobet L, Lahor-Soler E, Miranda-Rius J. On the Cellular and Molecular Mechanisms of Drug-Induced Gingival Overgrowth. Open Dent J. 2017;11:420-435.
- 44. Castro LA, Elias LS, Oton-Leite AF, de Spíndula-Filho JV, Leles CR, Batista AC, Mendonça EF. Long-term effects of nifedipine on human gingival epithelium: a histopathological and immunohistochemical study. J Oral Sci. 2010;52(1):55-62.
- 45. Brown RS, Arany PR. Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis. Oral Dis. 2015;21(1):e51-61.
- 46. Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, Wilkinson R, Ilde JR. Determinants of gingival overgrowth severity in organ transplant patients. An examination of the rôle of HLA phenotype. J Clin Periodontol. 1996;23(7):628-34.
- 47. Pernu HE, Knuuttila ML. Macrophages and lymphocyte subpopulations in nifedipine and cyclosporin A associated human gingival overgrowth. J Periodontol 2001;72(2):160-6.
- 48. Nurmenniemi PK, Pernu HE, Laukkanen P, Knuuttila ML. Macrophage subpopulations in gingival overgrowth induced by nifedipine and immunosuppressive medication. J Periodontol 2002;73(11):1323-30.
- 49. Duncan MR, Berman B. Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fifibroblasts by recombinant human interleukin- 6. J Invest Dermatol 1991; 97: 686–689.
- 50. Csiszar A, Wiebe C, Larjava H, Häkkinen L. Distinctive molecular composition of human gingival interdental papilla. J Periodontol 2007;78(2): 304-14.
- 51. Walsh P, Häkkinen L, Pernu H, Knuuttila M, Larjava H. Expression of fibronectin-binding integrins in gingival epithelium in drug-induced gingival overgrowth. J Periodontal Res 2007; 42(2): 144-51.
- 52. Lu HK, Tseng CC, Lee YH, Li CL, Wang LF. Flutamide inhibits nifedipine- and interleukin-1 beta induced collagen overproduction in gingival fibroblasts. J Periodontal Res 2010; 45: 451-457.
- 53. Sooriyamoorthy M, Gower DB, Eley BM. Androgen metabolism in gingival hyperplasia induced by nifedipine and cyclosporin. J Periodont Res 1990; 25(1): 25-30.
- 54. Steele RM, Schuna AA, SchreiberRT. Calcium antagonist- induced gingival hyperplasia. Ann Intern Med 1994;120:663-4.
- 55. Chin YT, Tu HP, Lin CY, Kuo PJ, Chiu HC, Liu SH, Lee SY, Fu E. Antioxidants protect against gingival overgrowth induced by cyclosporine A. J Periodontal Res. 2021;56(2):397-407.
- 56. Miranda J, Brunet L, Roset P, Farré M, Mendieta C. Reliability of two measurement indices for gingival enlargement. J Periodontal Res. 2012;47(6):776-82.
- 57. Marshall RI, Bartold PM. A clinical review of druginduced gingival overgrowths. Aust Dent J. 1999;44(4):219-32.
- 58. Lafzi A, Farahani RM, Shoja MA. Amlodipine-induced gingival hyperplasia. Med Oral Patol Oral Cir Bucal. 2006;11(6):E480-2.
- 59. Aldemir NM, Begenik H, Emre H, Erdur FM, Soyoral Y. Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. Afr Health Sci. 2012;12(4):576-8.
- 60. Torpet LA, Kragelund C, Reibel J, Nauntofte B. Oral adverse drug reactions to cardiovascular drugs. Critical reviews in oral biology & medicine. 2004;15(1):28-46.
- 61. Quenel L, Keribin P, Giran G, Tessier MH, Lesclous P. Amlodipine-induced gingival enlargement: A case report. J Stomatol Oral Maxillofac Surg. 2020;121(3):308-311.
- 62. Camargo PM, Melnick PR, Pirih FQ, Lagos R, Takei HH. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontol 2000. 2001;27:131-8.
- 63. Harel-Raviv M, Eckler M, Lalani K, Raviv E, Gornitsky M. Nifedipine-induced gingival hyperplasia. A comprehensive review and analysis. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 1995;79(6):715-22.
- 64. Hall EE. Prevention and treatment considerations in patients with drug-induced gingival enlargement. Curr Opin Periodontol. 1997;4:59-63.
- 65. Thompson AL, Herman WW, Konzelman J, Collins MA. Treating patients with drug-induced gingival overgrowth. J Dent Hyg. 2004;78(4):12.
- 66. Dannewitz B, Krieger JK, Simon I, Dreyhaupt J, Staehle HJ, Eickholz P. Full-mouth disinfection as a nonsurgical treatment approach for drug-induced gingival overgrowth: a series of 11 cases. Int J Periodontics Restorative Dent. 2010;30(1):63-71.
- 67. Dongari A, McDonnell HT, Langlais RP. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol. 1993;76(4):543-8.
- 68. Pejčić AS, Kesić LG, Živković VD, Obradović RR, Petrović MS, Mirković DS. Gingival overgrowth induced by nifedipine: Gingiva and drugs. Acta stomatologica Naissi. 2011;27(64):1104-9.
- 69. Mavrogiannis M, Ellis JS, Seymour RA, Thomason JM. The efficacy of three different surgical techniques in the management of drug-induced gingival overgrowth. J Clin Periodontol. 2006;33(9):677-82.
- 70. Ilgenli T, Atilla G, Baylas H. Effectiveness of periodontal therapy in patients with drug-induced gingival overgrowth. Long-term results. J Periodontol. 1999;70(9):967-72.
- 71. Ciancio SG, Bartz NW Jr, Lauciello FR. Cyclosporineinduced gingival hyperplasia and chlorhexidine: a case report. Int J Periodontics Restorative Dent. 1991;11(3):241-5.
- 72. Alims.gov.rs. 2021. ALIMS. [online] Available at: <https://www.alims.gov.rs/> [Accessed 22 September 2021].
- 73. Ustaoğlu G, Erdal E, Karaş Z. Influence of different antihypertensive drugs on gingival overgrowth: A crosssectional study in a Turkish population. Oral Dis. 2021;27(5):1313-9.